Switzerland-based pharmaceutical company, Novartis has launched the drug, Scapho for the treatment of plaque psoriasis in India.
Psoriasis is a severe, non-contagious autoimmune skin disease, characterized by red scaly patches covered with white scales. Plaque psoriasis is a more serious form of the condition.
‘Novartis Healthcare has launched the drug, Scapho in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.’
The generic name of Scapho is secukinumab, which is an injectable medicine and the first interleukin-17A (IL-17A) inhibitor to be approved in India for the treatment of moderate-to-severe plaque psoriasis in adult patients.
The company has launched the drug in the strength of 15mg in India, but it is already available in the US and Europe under the brand name Cosentyx.
"This approval marks a significant milestone in the treatment of psoriasis, providing a new and important first-line biologic treatment option for patients who are candidates for systemic therapy," Novartis said in a statement.